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Objectives: To assess the economic burden of cancer by estimating years of poten-
tial productive life lost (YPPLL) and costs of lost productivity due to premature can-
cer-related mortality across Europe. MethOds: We derived the number of cancer 
deaths by sex for 23 of the most common cancer sites in 30 European countries from 
GLOBOCAN. YPPLL were calculated by multiplying the number of cancer-specific 
deaths for each productive age group (15-64) by standard life expectancy at the 
mid-point for each age group. Using the human capital approach, we multiplied 
standardised YPPLL for each individual by country- age- and gender-specific annual 
wages from age of death until retirement following adjustments for labour force 
participation and unemployment. Costs were expressed in 2008€ . Results: All 
cancer sites combined generated a total of € 150.9 billion in premature mortality 
costs in Europe in 2008. Western Europe accounted for almost half of the total, 
followed by Northern (21%), Southern (21%) and Central & Eastern Europe (9%). 
Findings contrasted with YPPLL where Central & Eastern Europe had the highest 
burden. Male costs exceeded female costs by 88% in Europe as a whole (male: € 98.4 
billion; female: € 52.5 billion) and across all European regions. Lung was the most 
expensive site (€ 34.7 billion; 23% of total costs), followed by breast cancer (€ 13.6 
billion, 9%), colorectal cancer (€ 12.1 billion, 8%), brain & CNS (€ 9.1 billion, 6%) and 
pancreatic cancer (€ 7.5 billion, 5%). According to premature mortality cost per death, 
testicular cancer was the most expensive site (€ 2.5 million per death), followed by 
brain & CNS cancer (€ 481,512) and Hodgkin lymphoma (€ 474,559). cOnclusiOns: 
Lost productivity costs due to cancer-related premature mortality are significant in 
Europe. Productivity costs provide an alternative perspective on the cancer burden 
on society and may inform cancer control policy decisions.
ConCeptual papers
Cp1
InCremental Cost per QualIty-adjusted lIfe year GaIned? the need 
for alternatIve methods to evaluate medICal InterventIons for 
ultra-rare dIsorders
Schlander M.1, Garattini S.2, Kolominsky-Rabas P.3, Nord E.4, Persson U.5, Postma M.6, 
Richardson J.7, Simoens S.8, Sola Morales O.9, Tolley K.10, Toumi M.11
1University of Heidelberg, Wiesbaden, Germany, 2Mario Negri Institute for Pharmacological 
Research, Milano, Italy, 3University of Erlangen-Nuremberg, Erlangen, Germany, 4Norwegian 
Institute of Public Health, Oslo, Norway, 5The Swedish Institute for Health Economics, Lund, 
Sweden, 6Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, 
University of Groningen, Groningen, The Netherlands, 7Monash University, Melbourne, Australia, 
8KU Leuven, Leuven, Belgium, 9HITT, Barcelona, Spain, 10Tolley Health Economics, Buxton, UK, 
11University Claude Bernard Lyon 1, Lyon, France
Objectives: To critically appraise the problems posed by the systematic valua-
tion of interventions for ultra-rare disorders using conventional health economic 
analysis methods. MethOds: An international group of clinical and health eco-
nomic experts met in conjunction with the Annual European ISPOR Congress in 
Berlin/Germany, November 2012, to identify and deliberate underlying issues openly, 
adhering to the Chatham House rule. Results: The group reached a broad consen-
sus, including: The complexities of research and development new treatments for 
ultra-rare disorders (URDs) may require conditional approval and reimbursement 
policies, such as coverage with evidence development agreements, but should not 
be used as a justification for showing surrogate endpoint improvement only. As a 
prerequisite for value assessment, demonstration of a minimum significant clinical 
benefit should be expected within a reasonable timeframe. Regarding the economic 
evaluation of interventions for URDs, the currently prevailing logic of cost effective-
ness (using benchmarks for the maximum allowable incremental cost per quality-
adjusted year, QALY, gained) was considered inappropriate since it does not capture 
well-established social preferences regarding health care resource allocation. Such 
social preferences include, but are not limited to, a priority for care for the worse of 
(related to initial health state), for those with more urgent conditions (the so called 
“rule of rescue”), a relatively lower priority based upon capacity to benefit, and a 
dislike against “all or nothing” resource allocation decisions that might deprive 
certain groups of patients from any chance to access effective care. cOnclusiOns: 
Alternative paradigms to establish the “value for money” conferred by interventions 
for URDs should be developed with high priority. Such methods should capture and 
reflect prominent societal value judgments, beyond efficiency as conventionally 
defined by QALY maximization under a budget constraint.
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Decision analytical modelling represents an essential tool for undertaking health 
economic evaluation. Markov models provide a mathematical framework for such 
analyses, particularly in the context of assessing the cost-effectiveness of treat-
ments for chronic diseases where economic outcomes are typically extrapolated 
beyond the duration of clinical trials. However, structural uncertainty is a key chal-
lenge, to methodologists and decision makers alike, that has hitherto attracted 
insufficient attention. Best practice guidelines advocate the testing of structural 
assumptions through alternative modelling approaches or conducting scenario 
analyses. It should be recognised, however, that structural differences in model 
design represent a strength, rather than limitation, of the modelling process and 
in fields such as climate modelling, multi-model comparisons and ensemble pre-
dictions have been used extensively as the basis for more robust policy decisions. 
Methods for combining models represents an emerging field in climate modelling, 
but the simplest approach is to treat all models equally and the mean of all model 
predictions has been shown to improve on the ‘best’ model predictions in numerous 
studies. A weighted multi-model approach may also be developed, but this remains 
an area of ongoing debate. To date, health economists have not fully embraced the 
potential of the multi-model paradigm to reduce structural uncertainty. In this work, 
responsive to change particularly in oncology. Therefore the objective of this study 
was to determine the level of responsiveness of the EQ-5D in oncology. MethOds: 
A systematic review identified relevant articles reviewing responsiveness of the 
EQ-5D in adults (EMBASE, Medline). Effects sizes (ES) were calculated for the studies 
identified where not already reported. A meta-analysis was undertaken of the effect 
sizes: homogeneity of variance was assessed (fixed effects) and random effects 
models applied where there was significant heterogeneity. Responsiveness was also 
compared for improvement/deterioration in health status. Analyses were conducted 
in SPSS v18. Results: Data were available from 12 studies (3 breast, 2 prostate, as 
well as ovarian, lung and renal cancers) each with EQ-5D data at a minimum of 2 
time points leading to a total of 45 entries. The overall unweighted ES was -0.26 
(95%CI: -0.31 to -0.21), however there was significant heterogeneity in terms of effect 
sizes (Q(44) = 427.00, p< 0.001) which was accounted for using the random effects 
model (Q(44) = 39.58, p> 0.05). The overall weighted effect size (ES) was -0.17 (95%CI: 
-0.33 to -0.01). The weighted ES for improvement was 0.08 (95%CI: -0.02 to 0.18), and 
-0.52 (95%CI: -0.64 to -0.41) for deterioration. cOnclusiOns: There is considerable 
heterogeneity in the reported effect size of the EQ-5D. Responsiveness of the EQ-5D 
in oncology trials as measured by effect sizes is modest at best. The instrument 
appears to be more sensitive to deterioration in health status than to improvements. 
Further work will explore the ES of the EQ-5d in comparison with responsiveness 
of disease-specific measures and changes in health status.
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Objectives: The responsibility of caring for cancer patients, often suffering from a 
magnitude of health problems, can result in a considerable burden for their caregiv-
ers, both physically and psychologically. The objective of this study was to assess 
the status and extent of clinical research into the burden of caregiving for cancer 
patients. MethOds: ClinicalTrials.gov was searched for all cancer trials that con-
sidered caregiver burden, using a matrix of search terms such as ‘carer’, ‘burden of 
care’ or ‘caregiver’. The impact of geographical location or cancer type on the pro-
portion of trials assessing caregiver burden, the outcome measures used and the 
proportion of trials including caregiver burden as an outcome over time were inves-
tigated. Results: From a total of 36,184 cancer-focused trials documented world-
wide, 1,596 (4%) assessed caregiver burden. Outcome measures included caregiver 
quality of life (QoL), satisfaction with care and mood states. The impact of caregiver 
burden in cancer trials within different world regions varied, with the highest pro-
portion of trials that considered caregiver burden located in Mexico (23%) and Asia 
(14-22%). Trials for five major cancer types (breast, lung, prostate, colorectal, liver) 
assessed caregiver burden at similar frequency (4-5%). Evaluation of completed tri-
als demonstrated that the proportion of cancer trials considering caregiver burden 
increased from < 1% between 1997-2001 to 7% after 2012. cOnclusiOns: Fewer 
than 5% of all cancer trials documented worldwide have evaluated the impact of 
caregiver burden, although geographical variation does exist. The equal assess-
ment of caregiver burden across cancer types may suggest that no single cancer 
type is considered to have a higher degree of caregiver burden. Interestingly, while 
the number of total cancer trials evaluating caregiver burden documented to date 
is relatively low, the incidence has increased over the last 15 years, suggesting that 
the growing importance of caregiver burden is being recognised.
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Objectives: The recent European Medicines Agency (EMA) approval of crizotinib has 
highlighted the potential for regulatory approval to be gained on the basis of pivotal non-
comparative Phase II data. This research aims to determine the circumstances under 
which the EMA will approve submissions on this basis. MethOds: All publicly available 
European Public Assessment Reports (EPARs) were screened up to June 2013. Submissions 
that were based on pivotal Phase II data were identified and the acceptance decision, 
disease, and level of benefit were extracted. Results: Eight drugs (bevacizumab, bort-
ezomib, crizotinib, dasatinib, everolimus, gefitinib, imatinib, ofatumumab) across ten 
indications been submitted to the EMA on the basis of pivotal non-comparative Phase II 
data. All submissions were for entry indications except imatinib, which was also submit-
ted for two further indications on this basis. All, except crizotinib, were for indications 
with no alternative therapies and all were for onology indications except everolimus 
which was for subependymal giant cell astrocytoma (SEGA). All, except crizotinib, were 
EMA designated orphan medical products for these indications. One submission was 
rejected (bevacizumab), one was restricted (ofatumumab), and eight were approved. 
Top-line supportive Phase III data was only available in two submissions (crizotinib and 
everolimus). Overall response rates (ORRs) were the primary endpoints in all submis-
sions except imantinib and dasatinib in leukaemia indications and everolimus in SEGA. 
Rejected drugs had ORRs of 47% (ofatumumab, rejected subpopulation) and 38% (beva-
cizumab). Approved drugs had ORRs of 60% (crizotinib), 58% (ofatumumab, approved 
subpopulation), 40% (imatinib), and 35% (bortezomib). Despite low ORRs, imatinib was 
used to treat a disease with no licensed therapies (gastrointestinal stromal tumours), 
and bortezomib offered a 10% complete remission rate. cOnclusiOns: Pivotal Phase II 
data can support EMA approval if it demonstrates substantial clinical benefits for small 
patient populations with severe diseases that lack therapeutic alternatives.
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